AARD (Aardvark Therapeutics Inc) Short-Term Debt to Capital

Corporate company logo of Aardvark Therapeutics Inc (AARD)

This daily price chart for Aardvark Therapeutics Inc (AARD) reflects the price action of an asset with a debt-to-equity ratio of 0.01. The business is insulated from market cycles due to the stable demand for obesity therapies. Aardvark Therapeutics Inc (AARD) leverages partnerships with research centers to accelerate trials, while its competitive advantage is rooted in patents for specific small molecules.

Ratio of Short-Term Indebtedness to Capital: Aardvark Therapeutics Corp (AARD) for 02/14/2025 - 11/01/2026

Analytical breakdowns for Aardvark Therapeutics Inc

- stock quotes and analyst forecast:
Stock Price Aardvark Therapeutics Corp|AARD - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Aardvark Therapeutics Inc.|AARD - Enterprise Value
- book capitalization information:
Net Assets per Single Share Aardvark Therapeutics|AARD - Accounting Value of Company|Market Value to Book Value Ratio aardvarktherapeutics.com|AARD - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Aardvark Therapeutics Inc|AARD - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Aardvark Therapeutics|AARD - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Aardvark Therapeutics Inc.|AARD - Company Long-Term Liabilities|Company Short-Term Debts Aardvark Therapeutics|Quick Liquidity Indicator aardvarktherapeutics.com
- company profitability and valuation multiples indicators:
AARD - Profit After Payment of Taxes
Fundamental valuation:AARD Aardvark Therapeutics Corp
Brand item of Aardvark Therapeutics Inc.

Investors must assess the resilience of Aardvark Therapeutics Inc (AARD) amid intense pressure from pharmaceutical behemoths. This metric measures the share of liabilities maturing within one year relative to equity, determining the business's liquidity. This chart of the short-term liability-to-equity ratio reveals the company's dependence on external venture financing. Minimizing short-term debt reduces the risk of bankruptcy in the event of failed clinical trials.

Competitors of Aardvark Therapeutics Inc

Short-Term Debt to Capital ASND|MDGL (Madrigal Corp) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital CORT (Corcept Therapeutics)|Short-Term Debt to Capital rhythmtx.com RYTM|AKRO - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital MTSR (Metsera, Inc.)|MoonLake Pharma (MLTX) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Crinetics Corp|NAMS (NewAmsterdam Pharma) - Short-Term Debt to Capital|Short-Term Debt to Capital soleno.life|Short-Term Debt to Equity Ratio FOLD (Amicus Therapeutics, Inc.)|ETNB (89bio Inc) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Agios Pharmaceuticals Inc AGIO|GPCR - Short-Term Debt to Equity Ratio|MiMedx Group, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital rezolutebio.com|LXRX (Lexicon Pharmaceuticals, Inc.) - Short-Term Debt to Equity Ratio|MBX: Short-Term Loans to Capital Ratio|ALT (Altimmune Corp) - Short-Term Debt to Capital|Short-Term Debt to Capital Sagimet Biosciences Inc|Short-Term Debt to Capital BIOA|Short-Term Debt to Equity BMEA (biomeafusion.com)|Short-Term Debt to Equity Quince Therapeutics, Inc. QNCX|Fractyl Health Inc. (GUTS) - Current Liabilities to Capital|VTVT - Short-Term Debt to Equity|ATPC: Short-Term Debt to Equity|PLUR: Short-Term Debt to Capital|SYBX - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Lipocine|Matinas BioPharma Holdings Inc. (MTNB) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Spruce Biosciences (SPRB)|Short-Term Debt to Equity Ratio Galecto Corporation GLTO|Short-Term Debt to Capital CTCX (Carmell Corporation)|Short-Term Debt to Capital lumos-pharma.com LUMO|Organovo - Short-Term Debt to Capital|RDUS - Short-Term Debt to Capital